DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

DongKoo Bio & Pharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	11,021	25,372	15,713	12,514	19,557	4,881
Short-Term Investments	506.9	506.9	1,941	1,351	143.14	87.57
Trading Asset Securities	11,016	10,371	5,245	21,271	12,399	24,616
Cash & Short-Term Investments	22,545	36,250	22,898	35,136	32,100	29,585
Cash Growth	-33.02%	58.31%	-34.83%	9.46%	8.50%	168.63%
Accounts Receivable	25,727	19,876	19,879	18,503	15,774	17,455
Other Receivables	263.35	1,352	1,570	898.47	633.49	136.73
Receivables	28,694	23,953	22,449	19,402	16,408	17,592
Inventory	55,500	45,962	42,606	31,428	24,964	24,971
Prepaid Expenses	535.05	324.71	216.61	225.89	229.66	200.1
Other Current Assets	3,235	751.62	195.02	1,226	131.5	4.72
Total Current Assets	110,508	107,242	88,365	87,417	73,832	72,353
Property, Plant & Equipment	67,398	66,222	50,483	39,681	40,051	40,377
Long-Term Investments	71,441	50,419	39,800	33,619	35,498	26,495
Other Intangible Assets	5,431	13,172	10,903	9,010	3,048	2,081
Long-Term Accounts Receivable	-	-	-	-	-	16.66
Long-Term Deferred Tax Assets	4,954	3,162	291.5	6.95	-	-
Other Long-Term Assets	2,242	3,843	1,260	2,325	2,358	3,031
Total Assets	269,002	244,061	191,103	172,059	154,786	144,353
Accounts Payable	9,156	15,591	11,202	14,300	11,591	9,191
Accrued Expenses	11,386	11,337	10,274	9,637	6,496	4,683
Short-Term Debt	84,194	74,876	40,500	33,000	18,070	18,000
Current Portion of Long-Term Debt	1,750	-	-	-	5,000	-
Current Portion of Leases	673.47	681.03	842.63	567.83	453.23	523.99
Current Income Taxes Payable	2,396	3,325	1,638	2,576	1,978	915.59
Other Current Liabilities	9,960	9,441	8,863	5,963	6,434	7,194
Total Current Liabilities	119,516	115,251	73,318	66,044	50,022	40,508
Long-Term Debt	20,162	10,467	1,447	-	-	5,000
Long-Term Leases	215.84	616.95	1,014	754.22	770.27	219.01
Pension & Post-Retirement Benefits	-	0	277.09	0	205.81	0
Long-Term Deferred Tax Liabilities	-	8.89	4.5	140.93	2,315	3,034
Other Long-Term Liabilities	18,447	12,269	4,596	3,015	1,350	939.53
Total Liabilities	158,341	138,613	80,658	69,953	54,662	49,701
Common Stock	14,232	14,232	14,232	14,232	14,232	4,802
Additional Paid-In Capital	33,562	33,063	33,063	33,063	33,063	42,569
Retained Earnings	73,074	67,320	69,735	61,675	57,158	49,727
Treasury Stock	-10,545	-10,545	-7,137	-7,058	-4,062	-2,065
Comprehensive Income & Other	283.99	1,261	507.18	193.39	-266.18	-380.89
Total Common Equity	110,608	105,332	110,400	102,106	100,124	94,653
Minority Interest	53.96	116.03	44.92	-	-	-
Shareholders' Equity	110,661	105,448	110,445	102,106	100,124	94,653
Total Liabilities & Equity	269,002	244,061	191,103	172,059	154,786	144,353
Total Debt	106,996	86,641	43,804	34,322	24,294	23,743
Net Cash (Debt)	-84,451	-50,391	-20,906	813.88	7,806	5,842
Net Cash Growth	-	-	-	-89.57%	33.61%	-
Net Cash Per Share	-3051.40	-1845.19	-756.89	29.32	276.23	206.49
Filing Date Shares Outstanding	26.92	27.04	27.61	27.62	28.04	28.29
Total Common Shares Outstanding	26.92	27.04	27.61	27.62	28.04	28.29
Working Capital	-9,009	-8,009	15,046	21,374	23,811	31,844
Book Value Per Share	4109.22	3895.10	3998.84	3696.33	3570.78	3345.63
Tangible Book Value	105,176	92,160	99,497	93,096	97,076	92,572
Tangible Book Value Per Share	3907.44	3408.02	3603.92	3370.16	3462.08	3272.08
Land	13,262	13,262	10,849	10,849	10,584	10,584
Buildings	27,661	39,356	29,667	27,353	26,899	26,120
Machinery	10,321	30,310	19,768	17,741	17,813	16,838
Construction In Progress	11,357	7,823	10,694	1,451	887.9	844.54

Source: S&P Global Market Intelligence. Standard template. Financial Sources.